Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas

BackgroundAmplified MYCN oncogene resulting in deregulated MYCN transcriptional activity is observed in 20% of neuroblastomas and identifies a highly aggressive subtype. In MYCN single-copy neuroblastomas, elevated MYCN mRNA and protein levels are paradoxically associated with a more favorable clinical phenotype, including disseminated tumors that subsequently regress spontaneously (stage 4s-non-amplified). In this study, we asked whether distinct transcriptional MYCN or c-MYC activities are associated with specific neuroblastoma phenotypes.ResultsWe defined a core set of direct MYCN/c-MYC target genes by applying gene expression profiling and chromatin immunoprecipitation (ChIP, ChIP-chip) in neuroblastoma cells that allow conditional regulation of MYCN and c-MYC. Their transcript levels were analyzed in 251 primary neuroblastomas. Compared to localized-non-amplified neuroblastomas, MYCN/c-MYC target gene expression gradually increases from stage 4s-non-amplified through stage 4-non-amplified to MYCN amplified tumors. This was associated with MYCN activation in stage 4s-non-amplified and predominantly c-MYC activation in stage 4-non-amplified tumors. A defined set of MYCN/c-MYC target genes was induced in stage 4-non-amplified but not in stage 4s-non-amplified neuroblastomas. In line with this, high expression of a subset of MYCN/c-MYC target genes identifies a patient subtype with poor overall survival independent of the established risk markers amplified MYCN, disease stage, and age at diagnosis.ConclusionsHigh MYCN/c-MYC target gene expression is a hallmark of malignant neuroblastoma progression, which is predominantly driven by c-MYC in stage 4-non-amplified tumors. In contrast, moderate MYCN function gain in stage 4s-non-amplified tumors induces only a restricted set of target genes that is still compatible with spontaneous regression.

[1]  Martin Vingron,et al.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.

[2]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[3]  Andreas Prlic,et al.  Ensembl 2007 , 2006, Nucleic Acids Res..

[4]  J. Olson,et al.  N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. , 2006, Cancer research.

[5]  M. Tuchman,et al.  A population-based study of the usefulness of screening for neuroblastoma , 1996, The Lancet.

[6]  Filip Pattyn,et al.  Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation , 2004, Laboratory Investigation.

[7]  Sergio Contrino,et al.  ArrayExpress—a public repository for microarray gene expression data at the EBI , 2004, Nucleic Acids Res..

[8]  J. Maris,et al.  Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification , 2008, Oncogene.

[9]  Richard A Young,et al.  Chromatin immunoprecipitation and microarray-based analysis of protein location , 2006, Nature Protocols.

[10]  Giacomo Finocchiaro,et al.  Myc-binding-site recognition in the human genome is determined by chromatin context , 2006, Nature Cell Biology.

[11]  F. Berthold,et al.  Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. , 2003, Cancer letters.

[12]  Patrick Warnat,et al.  Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Lutz,et al.  E2F Proteins Regulate MYCN Expression in Neuroblastomas* , 2003, The Journal of Biological Chemistry.

[14]  Teuvo Kohonen,et al.  Self-Organizing Maps , 2010 .

[15]  Jelle J. Goeman,et al.  Testing association of a pathway with survival using gene expression data , 2005, Bioinform..

[16]  J. Khan,et al.  High Skp2 Expression Characterizes High-Risk Neuroblastomas Independent of MYCN Status , 2007, Clinical Cancer Research.

[17]  M. Schwab,et al.  Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. , 1996, Oncogene.

[18]  M. Schwab,et al.  MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells , 1998, Oncogene.

[19]  T. Sawada,et al.  MASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPAN Interim Report of a Mass Screening Study Group , 1984, The Lancet.

[20]  S. Berg,et al.  MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death , 2006, Molecular Cancer Therapeutics.

[21]  M. Schwab,et al.  Suppression of MYC by high expression of NMYC in human neuroblastoma cells , 1989, Journal of neuroscience research.

[22]  Hans Clevers,et al.  The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells , 2002, Cell.

[23]  U. Kees,et al.  Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. , 2006, Cancer research.

[24]  M. Schwab,et al.  MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. , 1998, Oncogene.

[25]  A. Pession,et al.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Westermann,et al.  Ataxin-2 promotes apoptosis of human neuroblastoma cells , 2003, Oncogene.

[27]  R. Green,et al.  Comparison of sample preparation methods for ChIP-chip assays. , 2006, BioTechniques.

[28]  E. Prochownik,et al.  The Ever Expanding Role for c-Myc in Promoting Genomic Instability , 2007, Cell cycle.

[29]  Wolfgang Huber,et al.  arrayMagic: two-colour cDNA microarray quality control, preprocessing , 2005, Bioinform..

[30]  Barbara Hero,et al.  Neuroblastoma: biology and molecular and chromosomal pathology. , 2003, The Lancet. Oncology.

[31]  J Pritchard,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Ishii,et al.  Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. , 2005, Cancer cell.

[33]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[34]  W. Sadee,et al.  Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line. , 1987, Cancer research.

[35]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[36]  Roland Eils,et al.  Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling , 2004 .

[37]  W. London,et al.  MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Philip R. Gafken,et al.  Myc influences global chromatin structure , 2006, The EMBO journal.

[39]  F. Speleman,et al.  Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. , 2006, Cancer research.

[40]  M. Schwab,et al.  MycN sensitizes neuroblastoma cells for drug-induced apoptosis , 1999, Oncogene.

[41]  J. A. Hickman,et al.  Why does stage 4s neuroblastoma regress spontaneously? , 1994, The Lancet.

[42]  H. Varmus,et al.  Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture , 1985, Nature.

[43]  Michael Baudis,et al.  Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  N. Cheung,et al.  The MYCN enigma: significance of MYCN expression in neuroblastoma. , 2006, Cancer research.

[45]  Teuvo Kohonen,et al.  Self-Organizing Maps, Second Edition , 1997, Springer Series in Information Sciences.

[46]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.

[47]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[48]  P. Ambros,et al.  Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. , 2001, Medical and pediatric oncology.

[49]  Alexander E. Kel,et al.  TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..

[50]  M. Eilers,et al.  Mechanisms of transcriptional repression by Myc. , 2006, Current topics in microbiology and immunology.

[51]  M Schwab,et al.  N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.